RNA, U7 small nuclear 186 pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU7-186P profile across patient tissues and cancer cell-line models. RNU7-186P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU7-186P is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, RNU7-186P RNA expression shows 10,973 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, BLCA, and KIRP as cancer lineages where RNU7-186P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU7-186P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU7-186P survival associations across molecular data types. RNU7-186P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU7-186P RNA expression–survival associations across cancer types. High RNU7-186P expression shows unfavorable associations in KIRC, DLBC, KIRP, THCA and LGG, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU7-186P RNA expression.
This table summarizes RNU7-186P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU7-186P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU7-186P shows lower tumor expression in BLCA, BRCA, KICH, THCA, COAD and READ. The BLCA box plot shows higher RNU7-186P RNA expression in normal versus tumor tissue (log2 FC = −1.017, t-test p = .001).
This table shows molecular features associated with RNU7-186P in patient tissues and cancer cell lines. In patient samples, RNU7-186P shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
